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Abstract
Background: Elevated blood glucose values are a prognostic factor in myocardial infarction (MI)
patients. The unfavourable relation between hyperglycemia and outcome is known for admission
glucose and fasting glucose after admission. These predictors are single measurements and thus not
indicative of overall hyperglycemia. Increased persistent hyperglycemia may better predict adverse
events in MI patients.
Methods: In a prospective study of MI patients treated with primary percutaneous coronary
intervention (PCI) frequent blood glucose measurements were obtained to investigate the relation
between glucose and the occurrence of major adverse cardiac events (MACE) at 30 days follow-
up. MACE was defined as death, recurrent infarction, repeat primary coronary intervention, and
left ventricular ejection fraction equal to or smaller than 30%.
Results: MACE occurred in 89 (21.3%) out 417 patients. In 17 patients (4.1%) it was a fatal event.
A mean of 7.4 glucose determinations were available per patient. Mean +/- SD admission glucose
was 10.1 +/- 3.7 mmol/L in patients with a MACE versus 9.1 +/- 2.7 mmol/L in event-free patients
(P = 0.0024). Mean glucose during the first two days after admission was 9.0 +/- 2.8 mmol/L in
patients with MACE compared to 8.1 +/- 2.0 mmol/L in event free patients (P < 0.0001). The area
under the receiver operator characteristic curve was 0.64 for persistent hyperglycemia and 0.59
for admission glucose. Persistent hyperglycemia emerged as a significant independent predictor (P
< 0.001).
Conclusion: Persistent hyperglycemia in MI has a stronger relation with 30-day MACE than
elevated glucose at admission.
Background
Acute myocardial infarction (MI) patients with hypergly-
caemia at admission have a worse prognosis than patients
that are normoglycemic at admission [1,2]. This relation
is found in both patients with diabetes mellitus (DM) and
in patients without DM [3-6]. It has been argued that in
patients without DM hyperglycaemia may be caused by
undetected diabetes [7,8]. Some patients who present
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with hyperglycaemia are indeed diabetic but many
patients with an admission glucose above 11.0 mmol/L
are not diabetic [9]. Elevated fasting glucose after admis-
sion for MI also predicts an unfavourable outcome [10-
12]. Admission glucose and fasting glucose as predictors
of outcome have the drawback that they are based on a
single measurement and thus are not indicative of persist-
ent hyperglycaemia [1-5,10,11,13,14]. A first step to
define persistent hyperglycaemia is to compute the mean
of all glucose values. However, an ordinary arithmetic
mean of glucoses ignores the unequal time distribution
between measurements [14]. The calculation of the time-
averaged glucose addresses this problem. In this post-hoc
analysis of data collected in a prospective study of MI
patients we sought to investigate whether persistent
hyperglycemia, defined as an elevated time-averaged glu-
cose over the first 48 hours after admission is a better pre-
dictor of major adverse cardiac events than elevated
glucose at admission.
Subjects and methods
Subjects
All patients with symptoms consistent with an acute MI of
>30 min duration, presenting within 24 hour after the
onset of symptoms and with a ST-segment elevation of
more than 1 mm (0.1 mV) in two or more contiguous
leads on the electrocardiogram and treated with primary
percutaneous coronary intervention (PCI) were included
in this study. At baseline age, gender, previous cardiovas-
cular disease defined as a history of coronary artery bypass
grafting (CABG), previous PCI, stroke and MI, existence of
DM, smoking status, Killip class, electrocardiographic site
of infarction, time of onset of symptoms, and time of hos-
pital admission were recorded. Patients were defined as
diabetic when treated with a diet, oral hypoglycaemic
drugs and/or insulin. The research protocol was reviewed
and approved by the medical ethics committee, and
patients were included after informed consent.
Glucose measures
Glucose levels were based on measurements of whole-
blood glucose (Modular System, Roche/Hitachi, Basel,
Switzerland). The first glucose available after admission
was defined as admission glucose. To determine the time-
averaged glucose level for an individual patient, a dedi-
cated computer algorithm interpolated all glucose meas-
urements into a curve, after which the area under this
glucose curve was calculated for the first 48 hours (persist-
ent hyperglycemia). The area under the curve was then
divided by 48 hours.
Enzymatic infarct size
Enzymatic infarct size was estimated by serial measure-
ments of creatine kinase (CK) fraction. CK was deter-
mined enzymatically on a Hitachi 717 automatic analyzer
according to the International Federation of Clinical
Chemistry (IFCC) recommendation at 30 degrees Celsius.
Frequent CK determinations were performed according to
a schedule that called for 4 to 8 measurements in the first
96 hours to calculate the area under the CK curves.
Left ventricular function
Left ventricular ejection fraction (LVEF) was measured
before discharge by radionuclide ventriculography or by
echocardiography. Radionuclide ventriculography was
performed with the multiple-gated equilibrium method
following the labeling of red blood cells of the patient
with technetium (99mTc-pertechnate). A General Electric
300 gamma-camera with a low-energy all-purpose paral-
lel-hole collimator was used. Global ejection fraction was
calculated by a Star View computer (General Electric, Wis-
consin, USA) using the fully automatic PAGE program.
LVEF as assessed by two-dimensional transthoracice-
chocardiography was reported as a descriptive grade of
function, using subjective visual assessment by two inde-
pendent observers. This approach is less time-consuming
than other methods, such as Simpson's rule or the wall
motion index score. Nevertheless, studies of subjective
visual assessment of LVEF suggest that this approach can
be at least as accurate as other methods [15]. A LVEF ≤
30% was defined as a poor left ventricular function before
the analysis [16].
Cardiac events
In all patients data were obtained with respect to mortal-
ity, recurrent myocardial infarction or repeat PCI during
the first 30 days after admission. The primary endpoint of
the study was the presence of a major adverse cardiac
event (MACE) during the first 30 days after admission for
acute MI. MACE was defined as the composite incidence
of death, recurrent infarction, repeat PCI or a LVEF ≤ 30%.
The combination of death and non-fatal major events as
recurrent infarction, repeat intervention, and heart failure
has been shown to be a valid predictor of 1-year mortality
[17,18]. If in one patient more than one event occurred,
these events accounted for one MACE. Recurrent myocar-
dial infarction was defined as the occurrence of symptoms
consistent with an acute MI of >30 min duration, signs of
infarction on the electrocardiogram, and a second
increase in serum CK level to more than twice the upper
limit of normal. If the CK level had not decreased to nor-
mal levels, a second increase of more than 200 IU per litre
over the previous value was regarded as indicative of a
recurrent infarction [19]. Repeat PCI was defined as angi-
oplasty performed within 30 days due to repeat signs and
symptoms of myocardial ischemia. If an event occurred
within 48 hours after admission persistent hyperglycemia
was calculated based on the values available before the
event.Cardiovascular Diabetology 2007, 6:2 http://www.cardiab.com/content/6/1/2
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Statistical analysis
Differences between groups were assessed with the Stu-
dent's t-test or the Mann-Whitney U-test. The Chi-square
test and the Chi-square test for trend were used to test dif-
ferences between proportions. Receiver operator charac-
teristic (ROC) curves were computed to assess the ability
of glucose-derived parameters to predict MACE or mortal-
ity. We also performed a Cox proportional-hazards regres-
sion model with factors at admission related to MACE at
least with a single-sided level of significance of 0.2 or less.
The Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, IL, USA) version 11.5 was used for all statistical
analysis.
Results
Between April 1, 1998 and October 1, 2001, 417 patients
were included. After 30 days a MACE had occurred in 89
patients (21.3%); in 17 patients (4.1%) it was a fatal event
and in 72 patients (17.3%) a non-fatal event. A repeat PCI
was performed in 20 patients (4.8%). Left ventricular
function data were available of 377 patients (90.4%). In
only 6 patients (1.4%) a reinfarction occurred within 30
days, whereas in 68 patients (18%) the LVEF was equal or
smaller than 30% was observed. Baseline demographic
and clinical characteristics of patients with a MACE and
patients without an event are represented in table 1 and
table 2. A mean of 7.4 glucose determinations were avail-
able per patient. Mean ± SD admission glucose was 10.1 ±
3.7 mmol/L in patients with a MACE versus 9.1 ± 2.7
mmol/L in event-free patients (P = 0.0024) (table 3).
Mean persistent hyperglycemia was 9.0 ± 2.8 mmol/L in
patients with MACE compared to 8.1 ± 2.0 mmol/L in
event-free patients (P < 0.0001). A total of 44 patients had
DM, of whom in two cases DM had not been diagnosed
before. In A glucose level at admission in the highest quar-
tile was observed in 34 DM patients (77.3%) and 38 DM
patients (86.4%) had persistent hyperglycemia.
The area under the ROC-curve for admission glucose was
0.59 (95% confidence interval 0.52–0.65) and for persist-
ent hyperglycemia was 0.64 (0.57–0.70). Factors related
with MACE in univariate analysis were previous cardio-
vascular events, hypertension, dyslipidemia, smoking,
positive family history, anterior site of infarction, Killip
class ≥ 2, multi-vessel disease, TIMI grade 3 flow after PCI,
admission glucose, and persistent hyperglycemia (table 1
and 2; all P <= 0.2). In the Cox proportional hazard
model, after correction for these factors anterior site of inf-
arction (hazard ratio (95% confidence interval) 4.06
(2.46–6.68), P < 0.001), Killip class ≥ 2 (1.97 (1.02–
3.83), P = 0.045), multi-vessel disease (1.99 (1.28–3.09),
P = 0.002), TIMI grade 3 flow after PCI (2.33 (1.26–4.31),
P = 0.007) and persistent hyperglycemia (1.12 (1.04–
1.20), P = 0.003) remained independent prognostic fac-
tors of MACE. In the subgroup of patients without known
diabetes mellitus also an independent relation of persist-
ent hyperglycemia with 30-day MACE could be observed
(1.19 (1.05–1.36), P = 0.006).
The positive relation between admission glucose and
MACE is illustrated in figure 1. In the lowest quartile of
admission glucose MACE occurred in 13.5% compared to
26.7% in the highest quartile (P for trend 0.023). That
persistent hyperglycemia has a stronger relation with 30-
day MACE than admission hyperglycemia is also illus-
trated in figure 1. The stepwise increase is more pro-
nounced with persistent hyperglycemia than with
admission hyperglycemia. The lowest quartile of persist-
ent hyperglycemia was 11.5% compared to 33.3% in the
highest quartile (P for trend < 0.0001).
30-day mortality increased with each quartile of persistent
hyperglycemia, with 1 patient that had died in the lowest
quartile versus 9 patients (8.6%) in the highest quartile
(table 4). All patients in the lowest quartile for admission
glucose survived and 8 patients (7.7%) and 7 patients
(6.7%) in the two highest quartiles did not survive the
first 30 days after admission (table 5).
The relation between admission glucose and persistent
hyperglycemia and reduced LVEF and increased enzy-
matic infarct size is strong (table 4 and 5). In the quartiles
of admission glucose the LVEF was 44.6%, 41.9%, 41.8%
and 40.7%, and in persistent hyperglycemia the LVEF was
45.3%, 43.3%, 40.9% and 39.4% (both P < 0.0001). The
mean ± SD enzymatic infarct size was 1001 ± 771 IU in
the lowest quartile of admission glucose versus 1690 ±
1783 IU in the highest quartile (P < 0.0001) and 919 ±
669 IU in the lowest quartile of persistent hyperglycemia
compared to 1579 ± 1402 IU in the highest quartile (P <
0.0001).
Discussion
In this study we observed that persistent hyperglycemia in
acute MI has a stronger relation with unfavourable short-
term outcome than glucose at admission. Previous studies
have primarily focused on the prognostic value of admis-
sion hyperglycaemia in both patients with and without
DM [1,2,5,13,20]. Some studies showed that an elevated
fasting glucose after admission also predicts unfavourable
outcome [10-12]. Only one study used a measure of per-
sistent hyperglycaemia in the analysis of the relation
between deregulation of the glucose metabolism during
MI [14]. In a study of 662 MI patients hyperglycaemia was
defined as the presence of a glucose level on admission or
a 4-day mean blood glucose level higher than 6.67 mmol/
L. A total of 457 patients (69.0%) had hyperglycaemia
and only 195 (29.7%) had previously known diabetes
mellitus. These patients developed more complications,
and had higher 28-day mortality [14]. The relation of per-Cardiovascular Diabetology 2007, 6:2 http://www.cardiab.com/content/6/1/2
Page 4 of 8
(page number not for citation purposes)
sistent hyperglycemia was observed both in the overall
population as in the subgroup of patients without known
diabetes.
Mechanisms of action
Several mechanisms can be postulated to explain the rela-
tion between acute and persistent hyperglycaemia and an
unfavourable outcome after reperfusion therapy for MI.
First, the relation between persistent hyperglycaemia and
outcome may be related to the presence of ongoing stress
in more severely ill patients. During myocardial ischemia
an increase in glucose levels is observed [21]. It has been
reported that glucose was related to adrenalin and cortisol
in patients with ST-segment elevation MI [22]. In the cur-
rent study, Killip class ≥ 2 on admission was more fre-
quent and enzymatic infarct size was larger, suggesting
that hyperglycaemia reflects extensive myocardial dam-
age.
The second possible explanation is that patients with
hyperglycaemia are likely to have diabetes, even if it has
not been diagnosed [7-9,23]. It has been described that
patients with DM have an impaired outcome after MI.
Potentially, patients with persistent hyperglycaemia are
more likely to have DM either known or unknown [9,11].
In our study, patients with DM had indeed an elevated
glucose at admission and a persistent hyperglycemia. The
number of patients without DM in the highest quartile of
admission glucose and persistent hyperglycemia was
approximately 2 out of 3 patients. Diabetes is associated
with extensive coronary artery disease and adverse out-
comes in MI patients. In the current study, elevated admis-
sion glucose and persistent hyperglycemia were related to
a higher prevalence of DM. Persistent hyperglycemia may
reflect insulin resistance. Insulin resistance is more often
present in non-diabetic patients with an acute MI com-
pared to matched controls [24]. When 181 patients
Table 2: Infarct characteristics, hemodynamic status and reperfusion treatment
Characteristics MACE group Event-free group P-value
Number of patients 89 328
Systolic blood pressure, mmHg (mean ± SD) 125 ± 23 132 ± 21 0.03
Diastolic blood pressure, mmHg (mean ± SD) 76 ± 17 78 ± 14 0.13
Heart rate (mean ± SD) 79 ± 15 73 ± 16 0.02
Anterior MI 69 (77.5) 131 (39.9) <0.001
Killip class 1 79 (88.8) 311 (95.0) 0.04
Killip class ≥ 2 10 (11.2) 17 (5.0)
Multi-vessel disease 58 (65.2) 156 (47.6) 0.002
TIMI grade 0 flow before PCI 60 (67.4) 212 (64.6) 0.36
Stent 48 (53.9) 184 (56.1) 0.82
GP IIb/IIIa receptor blocker 28 (26.2) 79 (24.1) 0.33
TIMI grade 3 flow after PCI 75 (86.2) 305 (93.3) 0.03
Data are number (%) unless otherwise indicated.
Table 1: Baseline characteristics patients with a major adverse cardiac events (MACE) and without an adverse event within 30-days
Characteristics MACE group Event-free group P-value
Number of patients 89 328
Age, years (mean ± SD) 62.5 ± 12.6 60.1 ± 11.8 0.11
Men 70 (78.7) 263 (80.2) 0.77
Previous cardiovascular events 17 (19.1) 47 (14.3) 0.17
Diabetes mellitus 11 (12.4) 33 (10.1) 0.33
Type 2 diabetes mellitus 11 (12.4) 28 (8.5) 0.29
Tablets 6 (6.7) 17 (5.1) 0.82
Insulin 2 (2.2) 13 (3.4)
Hypertension 32 (36.0) 87 (26.5) 0.06
Dyslipidaemia 16 (18.0) 75 (22.9) 0.20
Currently smoker 41 (46.1) 178 (54.3) 0.11
Positive family history 27 (30.3) 133 (40.5) 0.05
Data are numbers (%) unless otherwise indicated.Cardiovascular Diabetology 2007, 6:2 http://www.cardiab.com/content/6/1/2
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admitted with acute MI and no history of diabetes melli-
tus were compared to 180 matched controls without pre-
viously known diabetes or cardiovascular disease, glucose,
HbA1c, proinsulin, proinsulin/insulin ratio, triglycerides,
insulin resistance and fibrinogen were all consistently
higher in patients than controls (P < 0.01). Recently, in a
retrospective study, it was shown that non-diabetic
patients with signs of insulin resistance had impaired left
ventricular function recovery after coronary angioplasty
compared to patients without insulin resistance [25].
Finally, it is possible that hyperglycemia and concomitant
metabolic abnormalities may exacerbate myocardial dam-
age in MI. A recent study in 4102 non-diabetic patients
admitted for heart failure found a strong association
between admission glucose and short-term mortality [26].
Table 3: Relation between glucose measures and major adverse cardiac events
MACE group Event-free group P-value
Number of patients 89 328
Admission glucose 10.1 ± 3.7 9.1 ± 2.7 0.0024
Persistent hyperglycemia 9.1 ± 2.8 8.0 ± 2.0 <0.0001
Glucose data expressed as mmol/L (mean ± SD).
30-day major adverse cardiac events (MACE) according to quartiles of admission glucose and persistent hyperglycemia in MI  patients Figure 1
30-day major adverse cardiac events (MACE) according to quartiles of admission glucose and persistent hyperglycemia in MI 
patients. P value for trend in admission glucose is 0.023 and for persistent hyperglycemia is <0.0001.
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As in our study, the heart failure study does not allow con-
clusions whether hyperglycemia was an indicator or cause
of adverse outcome.
Role for insulin infusion
The obvious clinical difference between admission glu-
cose and persistent hyperglycemia is that hyperglycemia
during hospital stay is amenable to therapy, whereas
hyperglycemia already present on admission cannot be
modified. Therefore, in the clinical setting, the ultimate
proof that the hyperglycemic state may have harmful
effects on the ischemic myocardium is to demonstrate
that cardiac outcomes can be improved by strict glucose
regulation. The beneficial effect of an infusion of insulin
during myocardial ischemia has been suggested by a small
number of clinical studies, although they lacked a rand-
omized design and were not conclusive [27-29]. The only
large trials to investigate treatment focussed on hypergly-
cemia in MI patients were the Diabetes Insulin-Glucose in
Acute Myocardial Infarction (DIGAMI) studies. The DIG-
AMI included 620 patients with known diabetes mellitus
or serum-glucose concentrations of over 11.0 mmol/L
[30,31]. Patients were randomized for an insulin-glucose
infusion for 24 hours, followed by a minimum of 3
months of intensive insulin therapy or conventional treat-
ment. After 1 year, patients that had no previous insulin
treatment gained most by glucose-metabolism interven-
tion, with a mortality of 8.6 versus 18.0% in the control
group. For the study population as a whole, the authors
found an absolute reduction in mortality of 7.5%. The
recently published DIGAMI 2 randomized 1253 MI
patients with hyperglycemia to 24 hour insulin-glucose
infusion to obtain glucose levels between 7.0 and 10.0
mmol/L and subcutaneous long-term insulin treatment
thereafter, to 24 hours glucose control followed by stand-
ard glucose control thereafter, or to standard glucose con-
trol started after admission [32]. After a follow-up of 2
years no difference in mortality could be observed: 23.4%
versus 21.2% and 17.9% (NS). Glucose levels at admis-
sion averaged 12.7 mmol/L and fall to 9.1 mmol/L in the
intensive treatment group compared to 10.0 mmol/L after
standard treatment. The drop in glucose level of 3.4
mmol/L obtained in DIGAMI 2 was thereby smaller than
in their first trial (5.8 mmol/L). Moreover, in the smaller
Hyperglycemia: Intensive Insulin Infusion In Infarction
(HI-5) study with 240 patients, the mean blood glucose
level after 24 hours was 8.3 mmol/L in the treatment
group compared to 9.0 mmol/L in the conventional group
(NS) [33]. A mean insulin dose administered over this
time in the treatment group was (only) 1.9 units/hours.
An effect on mortality could not be observed.
The relation between hyperglycemia and outcome could
be one of the explanations for the lack of benefit of trials
using insulin in combination with glucose-potassium, i.e.
GIK [29,34-37]. Patients randomized to GIK suffered
more often from hyperglycemia after 24 hours. Future tri-
als have to determine whether or not to aim for strict glu-
cose regulation during acute MI, since in critically ill
patients it has been studied and proven to be effective in
critically ill patients [38,39]. The level of glucose levels
Table 5: Relation of quartiles of admission glucose with major adverse cardiac events, mortality and infarct size
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value*
Glucose range (mmol/L) 4.3–7.2 7.3–8.5 8.6–10.3 10.4–22.9
MACE (%) 14 (13.5) 23 (22.1) 24 (23.1) 28 (26.7) 0.023
30-day mortality (%) 0 (-) 2 (1.9) 8 (7.7) 7 (6.7) 0.003
LVEF (% ± SD) 44.6 ± 10.6 41.9 ± 11.4 41.8 ± 11.7 40.7 ± 12.0 <0.001
CK AUC (IU ± SD) 1001 ± 771 1283 ± 975 1505 ± 1349 1690 ± 1783 <0.001
MACE = major adverse cardiac events. LVEF = left ventricular ejection fraction. SD = standard deviation. CK = creatine kinase. AUC = area under 
the curve. *P value denotes P value for trend.
Table 4: Relation of quartiles of persistent hyperglycemia with major adverse cardiac events, mortality and infarct size
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value*
Glucose range (mmol/L) 5.4–6.9 7.0–7.6 7.7–8.8 8.9–20.6
MACE (%) 12 (11.5) 17 (16.3) 25 (24.0) 35 (33.3) <0.0001
30-day mortality 1 (1.0) 2 (1.9) 5 (4.8) 9 (8.6) 0.003
LVEF (% ± SD) 45.3 ± 9.8 43.3 ± 9.8 40.9 ± 12.3 39.4 ± 13.2 <0.001
CK AUC (IU ± SD) 919 ± 669 1430 ± 1547 1560 ± 1307 1579 ± 1402 <0.001
MACE = major adverse cardiac events. LVEF = left ventricular ejection fraction. SD = standard deviation. CK = creatine kinase. AUC = area under 
the curve. *P value denotes P value for trend.Cardiovascular Diabetology 2007, 6:2 http://www.cardiab.com/content/6/1/2
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obtained (4.4–6.1 mmol/L) were much lower than in
both DIGAMI, HI-5 and GIK trials.
Study limitations
Although in this analysis persistent hyperglycemia
depicted 30-day MACE over admission glucose the area
under the ROC curves for both measures were small.
Other factors than glucose deregulation must account for
unfavourable outcome after MI. On the other hand
admission glucose is seen as one among other measures
that help to predict outcome and possibly persistent
hyperglycemia could serve as a better prognostic value.
The number of patients in our analysis is not large,
although the level of significance for observed relations
was strong. The number of patients with diabetes was too
small to draw conclusions on the relation of persistent
hyperglycemia and outcome in the subgroup of patients
with diabetes mellitus. It would have been useful if we
had been informed about the degree of chronic hypergly-
cemia before the myocardial infarction, as reflected by gly-
cated hemoglobin (HbA1c). Unfortunately, we did not
systematically record HbA1c. Diabetes was diagnosed after
admission in two patients, although the true number of
diabetics might still have been higher. Finally, in a recent
study, fasting glucose was superior to admission glucose
with regard to 30-day mortality [12]. We did collect glu-
cose measures according to a time-scheme but had no
information whether the measures collected during the
morning were in the fasting state. Therefore, we could not
perform an analysis on the relation of fasting glucose.
Conclusion
In patients with acute MI treated with primary PCI, hyper-
glycemia defined by the time-averaged glucose during the
first 48 hours of hospital stay predicts unfavourable short-
term outcome better than admission hyperglycemia. Per-
sistent hyperglycemia could serve as a tool to compare
algorithms to obtain more strict glucose control in MI
patients, as well as in other critically ill patients. Possibly,
it could serve as a tool to recognize patients with
unknown diabetes. It is of great interest to see whether
studies directed to lower glucose levels after admission
lead to a reduction of unfavourable events and preserva-
tion of infarct-size.
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